New research from The New England Journal of Medicine presents a startling statistic: 28% of patients with active B12-related neurological damage showed no signs of anemia or macrocytosis on standard laboratory screening. This diagnostic blind spot represents a significant public health concern, as thousands of patients may be developing irreversible nerve damage while their physicians remain unaware due to false reassurance from normal test results.
The study examined patients with confirmed neuropsychiatric complications of B12 deficiency and found that conventional blood count analysis failed to detect the metabolic dysfunction occurring at the cellular level. While serum B12 combined with macrocytosis detection only achieved 72% sensitivity, methylmalonic acid testing proved far superior at 98.4% sensitivity. The findings underscore a fundamental limitation in current diagnostic algorithms and highlight the urgent need for clinicians to implement more specific testing protocols, particularly in patients presenting with unexplained neurological symptoms.
Read the full article on GMJ Newsroom.
Was this article helpful?
